TNBC, or triple-negative breast cancer, is a type of breast cancer whose cells lack three specific proteins that fuel most other breast cancers: estrogen receptors, progesterone receptors, and the HER2 protein. It accounts for roughly 12 to 20% of all breast cancer diagnoses. Because it’s missing those three targets, the hormonal therapies and HER2-blocking drugs that work against other breast cancers don’t work here, which makes treatment more challenging and the disease more aggressive on average.
Why “Triple-Negative” Matters
When someone is diagnosed with breast cancer, one of the first things doctors do is test the tumor for three biomarkers. Estrogen receptors and progesterone receptors tell the cancer to grow in response to hormones. The HER2 protein, when overproduced, also drives rapid cell growth. Most breast cancers test positive for at least one of these, which gives doctors a clear therapeutic target.
Triple-negative breast cancer tests negative for all three. That single distinction shapes nearly everything about how the disease behaves and how it’s treated. Without hormone receptors or excess HER2, the cancer can’t be starved by blocking estrogen or targeted with HER2-directed drugs. Treatment relies heavily on chemotherapy, immunotherapy, and in some cases, drugs that exploit specific genetic vulnerabilities in the tumor.
Who Is Most at Risk
TNBC tends to appear at a younger age than other breast cancers. The average age at diagnosis is about 51, compared to roughly 56 for non-triple-negative types. It also disproportionately affects Black women, whose incidence rates are approximately twice those of white women across all age groups. This disparity isn’t fully explained by access to care or screening differences. Research points to distinct biological factors in tumors from Black women, including differences in gene expression and tumor genetics, that may independently drive higher rates of TNBC.
Inherited mutations in the BRCA1 gene are another significant risk factor. TNBC is the breast cancer subtype most commonly linked to BRCA1 mutations. However, fewer than 20 to 25% of Black women with TNBC carry a BRCA1 mutation, suggesting that the molecular pathways leading to TNBC in this population may be fundamentally different from those in women of non-African descent.
How TNBC Behaves Differently
TNBC is generally faster-growing and more aggressive than other breast cancer subtypes. About 71% of triple-negative tumors are classified as high-grade, meaning the cells look very abnormal under a microscope and are dividing rapidly. By comparison, only about 20% of non-triple-negative breast cancers are high-grade. Triple-negative tumors also tend to be larger at diagnosis and are more likely to have already reached nearby lymph nodes.
When TNBC does spread beyond the breast, it favors different organs than other breast cancers. In one study, 50% of TNBC metastases went to the lungs, 26% to the liver, and 18% to the brain. Non-triple-negative breast cancers, by contrast, spread to the bones about 62% of the time. This pattern matters because brain and lung metastases can be harder to treat and often cause more noticeable symptoms earlier.
How It’s Found
The majority of triple-negative breast cancers, roughly 68%, are first detected through a physical finding like a lump, rather than on a routine screening mammogram. That’s a sharp difference from other breast cancers, where screening catches about half of cases. On a mammogram, TNBC most often appears as a mass without calcifications, typically with irregular or ill-defined edges. On ultrasound, these tumors usually look like dark (hypoechoic) or complex masses with irregular shapes and blurry borders.
Because these tumors grow quickly, a lump can appear and become noticeable in the interval between annual screenings. This is one reason TNBC is sometimes called an “interval cancer.” If you notice a new breast lump, especially one that seems to have appeared suddenly, prompt evaluation is important regardless of when your last mammogram was.
Treatment Approach
The backbone of TNBC treatment is chemotherapy, typically using a combination of two drug classes: anthracyclines and taxanes. For non-metastatic TNBC, chemotherapy is often given before surgery (called neoadjuvant treatment) with the goal of shrinking the tumor enough to allow a less extensive operation. When chemotherapy eliminates all detectable cancer in the surgical specimen, outcomes tend to be significantly better.
Adding platinum-based drugs to the chemotherapy regimen has shown promise in improving those response rates. But the biggest recent advance has been the addition of immunotherapy. In 2021, the FDA approved pembrolizumab (an immune checkpoint inhibitor) for use alongside chemotherapy in high-risk, early-stage TNBC. The treatment begins before surgery and continues afterward as a single agent. The approval was based on a trial of over 1,100 patients and applies regardless of a tumor biomarker called PD-L1. For metastatic TNBC, pembrolizumab plus chemotherapy is also approved, though only for tumors that test positive for PD-L1 at a certain threshold.
For patients whose tumors carry a BRCA1 or BRCA2 mutation, a class of drugs called PARP inhibitors offers another option. These drugs work by blocking a DNA repair enzyme that BRCA-mutant cancer cells depend on to survive. Without that repair pathway, damaged DNA accumulates in the cancer cells until they die. This approach, called synthetic lethality, has shown meaningful improvements in how long the disease stays controlled. PARP inhibitors are currently used in metastatic TNBC with confirmed BRCA mutations.
Survival Rates by Stage
Based on data from women diagnosed between 2015 and 2021, the five-year relative survival rates for TNBC are:
- Localized (cancer confined to the breast): 92%
- Regional (spread to nearby lymph nodes): 67%
- Distant (spread to other organs): 15%
- All stages combined: 78%
These numbers reflect treatments available at least five years ago. With the more recent approval of immunotherapy combinations and PARP inhibitors, outcomes for women diagnosed today are likely somewhat better than these statistics suggest. That said, TNBC survival rates remain lower overall than for hormone-receptor-positive breast cancers, largely because of its aggressive growth pattern and tendency to metastasize to difficult-to-treat organs.
Recurrence Patterns
One of the most important things to understand about TNBC is that its recurrence timeline is compressed compared to other breast cancers. The average time to relapse for TNBC is 19 to 40 months after diagnosis, while non-triple-negative breast cancers typically relapse at 35 to 67 months. Distant metastasis most commonly appears around the third year after diagnosis.
The flip side of this compressed timeline is that TNBC recurrence risk drops off more steeply after the first few years. With hormone-receptor-positive breast cancers, the risk of recurrence persists for a decade or longer. With TNBC, if you make it past the first three to five years without recurrence, the ongoing risk decreases more substantially. This doesn’t eliminate the need for follow-up, but it does mean the highest-risk window is more defined.